• News
    • Local
    • San Francisco
    • State
    • National
    • International
  • Perspectives
    • Opinions
    • Columns
    • Sports
  • Features
    • HIV & AIDS
    • Health
    • Seniors
    • Spirituality
    • Transgender / Transsexual
    • Real Estate
    • Everybody’s Business
    • Travel
    • Fitness
  • Arts & Entertainment
    • Theatre
    • Music
    • Books
    • Television
    • Film
  • Newspaper
    • Contact
    • Advertising Info
We The People
Voice of the LGBTQIA+ Community in the North Bay
  • News
    • Local
    • San Francisco
    • State
    • National
    • International
  • Perspectives
    • Opinions
    • Columns
    • Sports
  • Features
    • HIV & AIDS
    • Health
    • Seniors
    • Spirituality
    • Transgender / Transsexual
    • Real Estate
    • Everybody’s Business
    • Travel
    • Fitness
  • Arts & Entertainment
    • Theatre
    • Music
    • Books
    • Television
    • Film

Features/ HIV & AIDS/ Top Stories

FDA Backs Gilead’s HIV Prevention Drug Descovy for Use as PrEP

Reuters August 9, 2019

An FDA advisory panel on Wednesday voted in favor of Gilead Sciences Inc’s combination drug to reduce the risk of sexually acquired HIV infection in men and transgender women who have sex with men.

The treatment, Descovy, is a combination of emtricitabine and tenofovir alafenamide, and is already approved to treat chronic HIV.

When asked to assess the efficacy of Descovy for pre-exposure prophylaxis (PrEP) of HIV in men and transgender women who have sex with men, a patient population that forms the largest component of the PrEP market, the panel voted 16-2 in favor.

Related

NBC OUT

Generic HIV prevention drug coming in 2020, Gilead says

The recommendation is a shot in the arm for Gilead as its third best-selling HIV drug, Truvada, faces exclusivity loss in the United States, beginning 2020.

Truvada is largely boosted by its PrEP use, SVB Leerink analyst Geoffrey Porges said in a note ahead of the committee’s discussion. “Truvada grew at 15% last year, entirely due to PrEP.”

Descovy’s entry into the still underpenetrated PrEP market is vital to Gilead’s attempts to retain its Truvada patient base after the drug goes off-patent, he said.

Truvada accounted for 20.5% of the drugmaker’s total HIV franchise sales in 2018.

The panel’s backing also comes as a possible launch of Descovy for PrEP faces opposition from patient advocacy groups.

Related

NBC OUT

CEO behind HIV drug Truvada grilled on $3B in profits

They cite the scheduled U.S. launch next September of a generic version of the only currently approved prevention pill, Truvada, that could lower costs.

The panel, however, said there was not enough data to support the expansion of Descovy’s label for use as a preventive HIV drug for cisgender women. The panel voted 10-8 against its approval in this patient population.

Cisgender women form less than 7% of PrEP use and the prospect of Descovy’s label not including the population is not likely to impact the drug’s sales, Jefferies analyst Michael Yee said in a note ahead of the panel’s decision.

The FDA is yet to make a final decision on Descovy’s approval for PrEP. While the agency is not bound to follow the advice of its advisory panels, it usually does so.

Related Posts

Features /

Iowa enacts transgender bathroom bill and ban on gender-affirming care for minors

HIV & AIDS /

Tennessee shuns federal HIV funds

Top Stories /

Continuing the Fight for Equality: The Ongoing Struggle Against Anti-Drag Legislation

‹ Book Review: “Mostly Deadly Things” by Kristen Arnett › Civil Rights Probe Opened into Transgender Athlete Policy

Back to Top

  • News
  • Perspectives
  • Features
  • Arts & Entertainment
  • Newspaper
© We The People 2023
Powered by WordPress • Themify WordPress Themes